Melanoma Coverage from Every Angle
Advertisement
Advertisement

Recent News

Can Novel Imaging Technique Diagnose and Treat Skin Cancer Without Cutting Skin?
ASCO 2019: Continued Benefit Reported With Adjvuant Ipilimumab in Resected Melanoma
ASCO 2019: Neoadjuvant Therapy in Melanoma: Pathologic Response and Relapse
ASCO 2019: Nivolumab Plus Ipilimumab for Symptomatic Melanoma Brain Metastases
ASCO 2019: Whole-Brain Radiation vs. Observation for Melanoma Brain Metastases
EORTC Updates Sentinel Lymph Node Biopsy Protocol in Melanoma
Is BRAF V600E Mutation of Prognostic Value in Nonmetastatic Melanoma?
Sentinel Lymph Node Biopsy After Wide Local Excision for Melanoma of the Head and Neck
Pediatric Case of Spitzoid Melanoma: Focus on MAP3K8 Signaling Cascade
Are Girls at Higher Risk Than Boys of Developing Melanoma?
Role for Oxoglutarate Carrier in Formation of Melanoma
Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
AACR 2019: Entinostat Plus Pembrolizumab for Melanoma After Immunotherapy
FDA Fast Track Designation: Tebentafusp in Metastatic Uveal Melanoma
Skin Cancer 2019: Can Microneedle Technology Improve Skin Cancer Treatment?
AACR 2019: Can B Cells Predict Response to Immunotherapy in Melanoma?
AACR 2019: Impact of Probiotics and Fiber on Gut Microbiome and Immunotherapy Response
Society of Behavioral Medicine Conference 2019: Web-Based Intervention for Melanoma Prevention
FDA Proposes Updated Requirements for Sunscreen Products
2019 AAD: Using Artificial Intelligence to Diagnose Skin Cancers
2019 ASCO-SITC Symposium: Predicting Outcomes With Immunotherapy for Melanoma
Does Superfamily of Motor Proteins Play a Role in Invasive Melanoma?
Treatment of Uveal Melanoma With Extract From Primrose Plant
FDA Approves Pembrolizumab in Adjuvant Treatment of Melanoma
Computer-Designed Protein Mimics Interleukin-2 With Less Toxicity
MEK Inhibitor Under Study for Treatment of Brain Metastases From Melanoma
Predicting Which Melanoma Tumors Will Respond to Checkpoint Immunotherapy
Could the Protein Leucurogin Hinder the Growth of Melanoma Cells?
Vemurafenib Combination Therapy for BRAF -Mutated Melanoma
OpACIN Trial: Ipilimumab Plus Nivolumab in Stage III Melanoma
Do PPIs Affect the Efficacy of Immunotherapy in Metastatic Melanoma?


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.